CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Pelvic inflammatory disease - How up-to-date is this topic?
Changes
Version 1.1, revision planned in 2013.
Last revised in August 2009
February 2011 — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has advised that moxifloxacin should be restricted to second-line use for the management of pelvic inflammatory disease, because of the increased risk of liver reactions and QT prolongation [MHRA, 2011]. Issued in February 2011.
August 2010 — updated to include oral cefixime 400 mg as a single dose as an alternative to the intramuscular ceftriaxone component of the recommended antibiotic regimens [HPA and Association of Medical Microbiologists, 2010]. The lower age limit for quinolone prescriptions has also been raised from 16 to 18 years. Issued in September 2010.
March to August 2009 — converted from PRODIGY guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.
There are no major changes to the recommendations.
© NHS Institute for Innovation and Improvement